Therapeutic Indications

Agalsidase alfa is indicated for:

Fabry Disease

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 0.2 mg/kg every other week

Fabry Disease

Irrespective of gender only Adults (18 - 65 years old)

Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 0.2 mg/kg every other week

Contraindications

Active ingredient Agalsidase alfa is contraindicated in the following cases:

Amiodarone

No gender/age discrimination

Agalsidase alfa should not be co-administered with amiodarone since this substance has the potential to inhibit intra-cellular α-galactosidase activity.

Chloroquine

No gender/age discrimination

Agalsidase alfa should not be co-administered with chloroquine since this substance has the potential to inhibit intra-cellular α-galactosidase activity.

Gentamicin

No gender/age discrimination

Agalsidase alfa should not be co-administered with gentamicin since this substance has the potential to inhibit intra-cellular α-galactosidase activity.